Trials and Tribulations of EGFR and MET Inhibitor Combination Therapy in NSCLC
Author:
Publisher
Elsevier BV
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference19 articles.
1. Phase I results from a study of crizotinib in combination with erlotinib in patients with advanced nonsquamous non–small cell lung cancer;Ou;J Thorac Oncol,2017
2. Targeting MET in lung cancer: will expectations finally be MET?;Drilon;J Thorac Oncol,2017
3. Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC);Drilon;J Clin Oncol,2016
4. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC);Camidge;J Clin Oncol,2014
5. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling;Engelman;Science,2007
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cannabinoid receptor 2 expression in early-stage non-small cell lung cancers identifies patients with good prognosis and longer survival;Translational Lung Cancer Research;2022-10
2. Genotyping of cerebrospinal fluid in lung cancer patients with leptomeningeal metastasis;Thoracic Cancer;2022-07-27
3. Loss of Tpl2 activates compensatory signaling and resistance to EGFR/MET dual inhibition in v-RAS transduced keratinocytes;PLOS ONE;2022-03-24
4. Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer;Critical Reviews in Oncology/Hematology;2021-04
5. Development and biological investigations of hypoxia-sensitive prodrugs of the tyrosine kinase inhibitor crizotinib;Bioorganic Chemistry;2020-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3